Innovation is the key to success in the life sciences industry. But with the vast amounts of data being generated by clinical trials and other research, it can be difficult to know where to focus your efforts. COTA’s tailored, fit-for-purpose real-world data (RWD) can help.
COTA’s Summer Internship Program provides an opportunity for college students to explore their career interests, learn new skills, and receive mentorship from experts in the field. This year’s interns come from a variety of backgrounds and majors, and are working in a number of different areas within COTA.
As artificial intelligence revolutionizes healthcare, we must develop a regulatory framework to ensure ethical use of patient data for research and care delivery. But, what should those guardrails look like, and how will we deploy them across the life sciences and clinical care industries? Miruna Sasu shares her thoughts on AI in healthcare and its efficacy with patient data.
2022 has been a time of extraordinary growth at COTA including many new faces that we are proud to welcome to our team.
After working at one of the world’s leading global clinical research organizations, Noel joins us to continue his work advocating for patients and helping to advance therapeutic and diagnostic options for all.
COTA President & CEO, Miruna Sasu, gave a keynote speech at the DIA 2022 Global Annual Meeting on healthcare disparities. She shared her personal story of how her family benefited from clinical trials and how she is now working to open those opportunities for others.
We are so excited to welcome our 8 new interns for our 2022 internship program – learn a little bit more about each the newest additions to COTA.
COTA researchers and collaborators’s recent abstract in the European Hematology Association’s library, found that overall agreement between response categories was 65.1% among AML data.
After two years, COTA was back together in NYC for an in-person all-hands meeting. As much as we have learned to adapt to the world of remote work, there is no substitute for the connection, collaboration, and energy that comes from physically being in the same space.
Miami Cancer Institute, part of Baptist Health South Florida, will leverage COTA’s Real-World Analytics to drive standardization of care across all cancer patients
ViVE 2022 brought together thought leaders addressing key disparities and the future of healthcare. Our own C.K. Wang, alongside expert oncologists and technology innovators stressed the need for understanding what “precision oncology” really is.
I’m delighted to be leading COTA at this pivotal moment in history, when precision oncology and data science are advancing together at lightning speed. By working with partners across the healthcare continuum, we can guide cancer patients and their families down the path to clear, safe, personalized, and effective cancer care.
In this article in the scientific journal Blood Reviews, COTA researchers and collaborators share their views on the many sources of RWD and how to assess fit-for-purpose for use in RWE generation. They also review promising use cases for RWD, particularly for hematologic malignancies.
COTA is pleased to announce Kevin Schweikert has joined the company as vice president, life sciences. With more than 20 years of experience in life sciences business development, Kevin has partnered with the most innovative pharmaceutical companies in the business, and the vendors these companies turn to for real-world data and analytics.
Working with the FDA and now COTA Laura describes why real-world data is an integral part of today’s patient care.
Paige Whitney will join the executive leadership team as Senior Vice President of Life Sciences. Paige is responsible for growing the company’s industry partnerships and strengthening COTA’s position as a leading provider of oncology RWD.
Diversity in clinical trials is a change that needs to be made in order to make all efforts more efficient and develop a better ending result for patients. Karla Feghali and Laura Fernandes detail why this is so necessary moving forwards.
RWD can help us address one of the most challenging systemic issues in healthcare: disparities in health outcomes perpetuated by uneven access to services and the unconscious bias of humans and technology
This will be the year that patient centricity drives drug development and care delivery decisions.
Oncologists believe it is important for all clinical trials to include a real-world data component, and the overwhelming majority would urge pharmaceutical companies and cancer research groups to use real-world data in all clinical trials as well.
Dr. Califf is a staunch advocate for the use of real-world data (RWD) and real-world evidence (RWE) in the clinical trial ecosystem, with a long history of leveraging RWD and RWE to transform the life sciences community.
Interested in receiving updates on our latest posts?
